Validation study including over 2,700 patients confirms the prognostic performance of Stratipath Breast
The study, which was recently published in Breast Cancer Research and conducted by Karolinska Institutet in Stockholm, validates the prognostic performance of Stratipath Breast in a large retrospective cohort of over 2,700 patients from two independent clinical sites.
Stratipath breast is demonstrating considerable agreement with established gene expression test
The findings showed that the Stratipath Breast analysis identified 49.6% of the clinically intermediate tumors as low risk and 50.4% as high risk. The Prosigna assay classified 32.5%, 47.0% and 20.5% tumors as low, intermediate and high risk, respectively. Among Prosigna intermediate-risk tumors, 47.3% were stratified as Stratipath low risk and 52.7% as high risk. In addition, 89.7% of Stratipath low-risk cases were classified as Prosigna low/intermediate risk. The overall agreement between the two tests for low-risk and high-risk groups (N = 124) was 71.0%, with a Cohen’s kappa of 0.42. For both risk profiling tests, grade and Ki67 differed significantly between risk groups.
High-Impact research in Annals of Oncology lays critical foundation for Stratipath Breast’s AI-based cancer diagnostics
This published high-impact scientific article from Karolinska Institutet shows that AI-supported image analysis can stratify intermediate-grade breast cancers into low or high risk categories This has strong prognostic value and potential to revolutionise breast pathology.
